DPLG3
DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC50 of 4.5 nM. DPLG3 inhibits mouse i-20S with IC50 of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research[1][2][3].
Product Specifications
CAS Number
1801379-22-5
UNSPSC
12352209
Target
NF-κB; Proteasome
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dplg3.html
Purity
99.18
Solubility
10 mM in DMSO
Smiles
FC(C=C1)=CC=C1C[C@H](NC([C@H](CC(NOC(C)(C)C)=O)NC(CCC2=CC=CC=C2)=O)=O)C(NCC3=CC=CC4=C3C=CC=C4)=O
Molecular Formula
C37H41FN4O5
Molecular Weight
640.74
References & Citations
[1]Moallemian R, et al. Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. Biochem Pharmacol. 2020 Jul;177:113964.|[2]Sula Karreci E, et al. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 Dec 27;113 (52) :E8425-E8432. |[3]Basler M, et al. On the role of the immunoproteasome in transplant rejection. Immunogenetics. 2019 Mar;71 (3) :263-271.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
NF-κB1/p50; RelA/p65
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
